GlassScriptPhysician profile
Jill Miller
NPI 1710612635
$4,070.70
in general payments reported to CMS, 2019-2025
33 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $934 · 2024: $1,702 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,026 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,025.70 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.88 | 2023-2025 | |
| Novo Nordisk INC | $459.19 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $358.02 | 2023-2025 | Rexulti |
| Ucb, INC. | $301.13 | 2024-2025 | Briviact, Fintepla |
| Axsome Therapeutics, INC. | $288.16 | 2023-2025 | Auvelity |
| Neurelis, INC. | $217.28 | 2023-2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $198.66 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $193.52 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $140.81 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Genzyme Corporation | $137.12 | 2023 | |
| Jazz Pharmaceuticals INC. | $134.14 | 2023 | Epidiolex |
| Braeburn INC. | $131.95 | 2024 | Brixadi |
| Indivior INC. | $130.61 | 2023-2025 | Sublocade |
| Lilly USA, LLC | $91.59 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $74.05 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.85 | 2023-2025 | Caplyta |
| Verity Pharmaceuticals INC. | $64.30 | 2024-2025 | Tlando |
| Janssen Pharmaceuticals, INC | $62.61 | 2024-2025 | Spravato, Invega Sustenna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.98 | 2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $59.89 | 2024 | |
| Exact Sciences Corporation | $49.81 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $34.94 | 2024-2025 | Airsupra, Farxiga |
| Ardelyx, INC. | $27.04 | 2024 | Ibsrela |
| Amgen INC. | $22.18 | 2025 | Repatha, Otezla |
| Acadia Pharmaceuticals INC | $20.67 | 2024 | Nuplazid |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.38 | 2024 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $17.14 | 2023 | Trintellix |
| Eisai INC. | $15.88 | 2024 | |
| Neurocrine Biosciences, INC. | $15.85 | 2025 | |
| Organon LLC | $14.28 | 2025 | Nexplanon |
| Azurity Pharmaceuticals, INC. | $14.06 | 2025 | Edarbi |
| Halozyme INC | $13.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.